$0.94
+0.05 (+5.88%)
Open$0.93
Previous Close$0.89
Day High$0.96
Day Low$0.90
52W High$15.73
52W Low$9.25
Volume—
Avg Volume786.0K
Market Cap181.09M
P/E Ratio28.68
EPS$0.48
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,522.1% upside
Current
$0.94
$0.94
Target
$15.22
$15.22
$10.64
$15.22 avg
$24.41
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 173.28M | 180.17M | 139.91M |
| Net Income | 5.24M | 5.71M | 4.80M |
| Profit Margin | 3.0% | 3.2% | 3.4% |
| EBITDA | 9.18M | 9.37M | 7.10M |
| Free Cash Flow | 6.14M | 5.00M | 3.87M |
| Rev Growth | +9.0% | +21.8% | +16.2% |
| Debt/Equity | 0.62 | 0.48 | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |